References in periodicals archive ?
Oritavancin, Targanta's lead product candidate, is a once-daily, semi- synthetic glycopeptide antibiotic with rapid bactericidal activity against all clinically relevant serious gram-positive infections, including multi- resistant strains.
The woodmice and bank voles may have been exposed in the woodland to either avoparcin (a glycopeptide antibiotic related to vancomycin) or fecal material from farm animals; however, avoparcin had not been used for any livestock raised in proximity to the sites, and the samples (including the badger samples) were taken after the use of avoparcin as a growth promoter had been banned.
Goldmann served on CDC's Hospital Infection Control Practices Advisory Committee and chaired the taskforce that developed national guidelines for the use of a glycopeptide antibiotic, vancomycin.
Parr will discuss the novel glycopeptide antibiotic, oritavancin, Targanta's lead drug candidate, its mechanisms of action and its activity against antibiotic-resistant pathogens.
Enterococci are ubiquitous in humans and animals and have a propensity for uptake and transfer of glycopeptide antibiotic resistance (3); therefore, the emergence of glycopeptide-resistant enterococci (ORE) in humans is a public health concern.
Oritavancin, Targanta's lead product candidate, is a once-daily, semi-synthetic glycopeptide antibiotic with rapid bactericidal activity against all studied clinically relevant serious gram-positive pathogens, including multi-resistant strains.
Oritavancin, a novel glycopeptide antibiotic, is Targanta's lead product currently in post-Phase III clinical development.
Oritavancin is a semi-synthetic glycopeptide antibiotic in development for the treatment of a broad range of resistant gram-positive bacterial infections.